News

At the 2025 Revolutionizing Atopic Dermatitis Conference, Leon Kircik, MD, highlighted the safety of JAK inhibitors, clarified misconceptions around boxed warnings, and discussed the clinical relevance of recent label updates for abrocitinib.

At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Catch up on coverage from the first day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

At RAD 2025, Mona Shahriari, MD, emphasized the cumulative life course impairment of AD in pediatric and adult patients, highlighting its impact on sleep, mental health, family well-being, and quality of life.

Discover groundbreaking insights from the RAD 2025 conference on roflumilast's potential to transform treatment for infant atopic dermatitis.

At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.

A poster at RAD 2025 detailed the patient-reported outcomes across skin types and racial groups.

Co-chairs Jonathan Silverberg, MD, PhD, MPH, and Raj Chovatiya, MD, PhD, MSCI, gave insight into what attendees can look forward to at this year's meeting.

Arcutis Biotherapeutics showcases promising long-term results of Zoryve for atopic dermatitis in young children at RAD 2025, emphasizing safety and efficacy.

Discover the latest breakthroughs in atopic dermatitis treatment and expert insights from the RAD dermatology conference in Nashville.

Catch up on what to expect at this year's RAD conference in Nashville, Tennessee.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

The OS-01 peptide formulation enhanced skin barrier function and reduced inflammation, showing promising results in a 12-week clinical trial.

Tristan Hasbargen, PA-C, led a hands-on suturing workshop at the Fall Clinical NP/PA Conference, enhancing skills in surgical dermatology.

Zasocitinib emerges as a promising oral therapy for psoriasis and psoriatic arthritis, showcasing superior selectivity and safety compared to traditional JAK inhibitors.

Acne is increasingly recognized as a chronic condition, affecting diverse populations and demanding innovative treatment strategies and equitable care access.

In part 3 of this conversation, Adam Friedman, MD, FAAD, discusses the need for unity in advancing lichen planus care and research.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Market pullbacks tempt investors to time the market, but history shows staying invested beats guessing the highs and lows—time > timing.

Jonathan Silverberg, MD, PhD, MPH, walks through what to look out for in AD management.

Discover the latest advancements in dermatology in our June issue, including FDA approvals, innovative treatments, and expert insights shaping patient care today.

In part 2 of this conversation, Adam Friedman, MD, FAAD, discusses new data on lichen planus treatment trends, unmet needs, and the promise of innovative therapies.

Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.

This review of the latest dermatologic studies includes insights into clinical manifestations of mpox infection, therapeutic modulation of Demodex density via isotretinoin, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

New research highlights the importance of tinted sunscreens with iron oxides for effective protection against visible light-induced skin pigmentation, especially for darker skin tones.

Jonathan Silverberg, MD, PhD, MPH, shares his insights on treating and managing CHE.

The National Psoriasis Foundation Seal of Recognition program has expanded to prescription drugs, making roflumilast the first to achieve the indication.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.